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Abstract
Venous thromboembolism (VTE) is an illness that has a 
potentially life-threatening condition that affects a large 
percentage of the global population. VTE with pulmonary 
embolism (PE) is the third leading cause of death after 
myocardial infarction and stroke. In the first three months 
after an acute PE, there is an estimated 15% mortality 
among submassive PE, and 68% mortality in massive PE. 
Current guidelines suggest fibrinolytic therapy regarding 
the clinical severity, however some studies suggest a 
more aggressive treatment approach. This review will 
summarize the available endovascular treatments and the 
different techniques with its indications and outcomes.
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Core tip: Venous thromboembolism (VTE) is an illness 
that is potentially life-threatening condition that affects 
a large percentage of the global population. VTE is the 
third leading cause of death related with cardiovascular 
pathology after myocardial infarction and stroke. This 
article summarizes the clinical management and em-
phasizes which interventional treatments that exist and 
the most effective ones to treat massive and submassive 
pulmonary embolism.
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Venous thromboembolism (VTE) is a life-threatening 
condition that affects a large percentage of the global 
population; VTE includes the deep vein thrombosis (DVT) 
and pulmonary embolism (PE). The incidence rate of 
VTE is 100 cases per 100000 inhabitants in Europe[1] 
and 160 per 100000 inhabitants in the United States[2]. 
VTE is the third leading cause of death after myocardial 
infarction and stroke. In the first three months after 
an acute PE, there is an estimated of 15% mortality 
among submassive PE, and 68% mortality in massive 
PE[3]. Acute PE is also the leading cause of pulmonary 
hypertension and right ventricular failure[4].
From the clinical point of view, two different situ-
ations need to be considered, prognosis and therapeutic 
management. For a massive PE there are three different 
treatments options: (1) systemic thrombolysis; (2) Sur-
gical pulmonary embolectomy; and (3) Endovascular 
techniques[5]. Other authors also advocate to implant 
an inferior vena cava filter (IVCf) in massive PE to 
prevent further thrombus migration and avoid higher 
thrombotic load or avoid anticoagulation therapy. 
According to the clinical guidelines of the American 
College of Chest Physicians (ACCP) an interventional 
approach, in an acute massive PE, currently is only 
considered the treatment of choice when a systemic 
thrombolysis therapy fails or is contraindicated[6]; 
however other authors advocate the use of the fo-
llowing procedures: Catheter directed therapy (CDT), 
mechanical fragmentation, thrombectomy procedures 
as a more aggressive therapeutic management that 
can provide excellent results in a massive PE[7-10]. Since 
there are a variety of CDT and thrombectomy methods, 
more prospective studies are still needed to refine the 
interventional approach protocol and determine the 
safest techniques in larger cohorts. This review will 
outline the different clinical presentation of PE, and 
will summarize the available endovascular treatments 
and the different techniques with its indications and 
outcomes. 
TYPES AND DEFINITIONS OF PE
The two main subtypes of PE that are necessary to 
address are the submassive (intermediate risk) and 
massive PE (high risk). The most frequent clinical 
symptoms are dyspnea (82%) and chest pain (49%), 
but it can also present: Cough (20%), syncope(14%) 
and Hemoptysis (7%)[3]. 
Massive PE is defined as an hemodynamically un-
stable condition which has clinical presentation with 
low blood pressure (systolic pressure < 90 mmHg 
or a decrease of more than 40 mmHg in baseline 
systolic pressure) and may develop a cardiac arrest. 
Other clinical manifestations related to hypotension 
may be present, such as tissue hypoperfusion and 
hypoxemia[11]. 
Submassive PE (intermediate risk) is defined as 
a hemodynamically stable condition (normal blood 
pressure) with a right ventricular dysfunction or elevated 
cardiac biomarkers which can develop a reduced 
workload and an increased strain on the heart[5].
It should not be confused with the radiological 
definitions of “massive” PE in which the criteria are 
related to the quantity of thrombus within the pul-
monary trunk or the arterial pulmonary branches 
instead of the clinical presentation of the PE. A “massive” 
PE, from the radiological point of view, is described as 
a reduction of of lung perfusion in one lung (> 90%) or 
total occlusion of a main pulmonary artery diagnosed 
with a pulmonary CT angiography[12].
Mortality in massive PE patients with hemodynamic 
shock can reach a 68% in the first hours after dia-
gnosis[13]. However In submassive PE the mortality is 
lower compared to a massive PE.
The American College of Chest Physicians in their 
guidelines differentiates the considered treatment for 
both situations[6]. While in the massive PE, thrombolysis 
(Class Ⅱa, Level of Evidence B) is recommended as 
the first option, in a submassive PE the thrombolysis 
is controversial. Thrombolysis may be indicated in 
submassive PE with a poor prognosis (RV dysfunction, 
severe respiratory failure, myocardial necrosis) and low 
risk of bleeding (Class Ⅱb level of evidence C). In the 
rest, thrombolysis is not recommended (Class Ⅲ, level 
of evidence B).
PATHOPHYSIOLOGY OF MASSIVE PE
The severity of a massive PE is directly related to the 
amount of thrombus occluding the pulmonary arteries 
and the underlying cardiopulmonary status of the 
patient, which causes hemodynamic instability[14]. A 
significant obstruction of the pulmonary vascular bed 
produces hypoxemia and results in the release of potent 
vasoconstricting substances that further aggravate 
the systemic hypoxia, with an increase in pulmonary 
arterial resistance that can cause an elevated right 
ventricular afterload[15]. Right ventricular overload 
produces hypokinesia and ventricular dilatation with 
tricuspid regurgitation; in which can eventually lead 
to right ventricular failure. Increased pressure in the 
right ventricle (RV) may cause alteration in the cardiac 
wall with ischemia or myocardial infarction due to an 
increase in the demand for oxygen and a decrease in 
the supply. In addition, stress on the myocardial wall 
along with systemic arterial hypotension decreases 
the perfusion to the coronary arteries, which can also 
lead to RV ischemia with or without infarction[16]. All of 
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these changes may lead to RV failure, diminished left 
ventricular output and life-threatening hemodynamic 
shock[13].
MASSIVE PE DIAGNOSIS
Clinical manifestations play an important role in the 
differential diagnosis between massive PE and non-
massive PE. Hemodynamic instability with suspected PE 
(blood pressure < 90 mmHg) establishes the diagnosis 
of massive PE, while to diagnose a submassive PE it 
is essential to rule out right ventricular dysfunction by 
echocardiography and/or elevated cardiac biomarkers. 
Computed tomography pulmonary angiography (CTPA) 
should report the size of the thrombus and percentage 
of occlusion of the pulmonary arteries. The amount and 
size of the thrombus should not be used to differentiate 
between clinical massive and submassive PE. If the 
patient has a good pulmonary reserve, a massive 
embolism (high thrombotic load) does not always have 
an hemodynamic repercussion. CTPA also provides 
information on pulmonary vascular perfusion as well as 
other chest findings such as pleural effusion, pneumonic 
foci, neoplasia, etc. Finally CTPA can also describe RV 
failure by comparison of the diameter of the RV with 
the left ventricle (LV) and determine RV dilatation (RV/
LV ratio > 1)[17]. The main echocardiographic signs of 
submassive PE are RV dilation and septum deviation to 
the LV[16,18]. Clinical history and physical examination are 
the key to establish the prognostic signs of severity. The 
International Cooperative Pulmonary Embolism Registry 
(ICOPER) identifies many clinical factors that can predict 
an increased mortality at 30 d (Table 1)[3]. Ventilation/
perfusion (V/Q) scanning is reserve as a diagnostic 
tool only in patients in whom CTPA is contraindicated 
or inconclusive and V/Q scanning should only be 
performed in patients with normal chest radiograph[19].
Other supportive diagnostic tools include elevated 
d-dimer, cardiac biomarkers, DVT diagnosed with 
lower limb duplex, and RV dysfunction and elevated 
pulmonary pressure with echocardiography[20].
MEDICAL TREATMENT AND SUPPORT IN 
MASSIVE AND SUBMASSIVE PE
It is important from the outset to establish if the PE has 
hemodynamic stability, and to choose the appropriate 
therapeutic guideline. The ACCP[6] in its guidelines 
for the treatment and management of pulmonary PE 
recommends systemic fibrinolytic agent for massive 
PE with hemodynamic instability and low bleeding 
risk (Grade 1B). While a patient with a low risk PE it is 
only recommended anticoagulation therapy. However, 
the treatment of submassive PE is controversial. For 
submassive PE, the ACCP currently recommends, in 
selected patients with acute PE who deteriorate after 
starting anticoagulant therapy but have yet not develop 
a hypotension and who have a low bleeding risk, they 
suggest systemically administered fibrinolytic therapy. 
In patients who have a higher risk of bleeding with 
systemic fibrinolytic therapy, the physicians with access 
to CDT are likely to choose this treatment over systemic 
fibrinolytic therapy[6].
Massive and submassive PE has an important 
mortality in the first few hours, therefore urgent 
diagnosis and therapeutic approach is required[13]. It 
has been established that more than 25% of patients 
diagnosed with massive PE with hemodynamic ins-
tability die within the first two weeks[3,7]. The first 
therapeutic measures with fluid therapy and vasoactive 
drugs (dopamine, noradrenaline, etc.) should be 
directed to correct the hypotension and the RV failure. 
It is important to maintain patent airway with good 
oxygen supply, if necessary with tracheal intubation and 
mechanical ventilation, to improve oxygenation and 
prevent respiratory failure. 
Anticoagulation treatment, if there is no contrain-
dication, should be administered immediately. Low-
molecular-weight heparin (LMWH) or unfractionated 
heparin can be used in therapeutic range. ACCP 
recommends systemic thrombolysis in the case of 
massive PE with haemodynamic instability, and low 
bleeding risk. Urokinase (UK) and recombinant tissue 
plasminogen activator (r-TPA) are used as fibrinolytic 
substances. For massive PE, standard doses are: UK 
4400 IU/kg per hour in 12-24 h, streptokinase 250000 
IU bolus and then 100000 U/h for 12-24 h, or 1500000 
U over 2 h, and 100 mg r-TPA over 2 h. The UKEP study 
did not demonstrate significant differences between 12 
and 24-h therapeutic regimens in terms of safety and 
efficacy[21]. Other studies have used higher doses of 
UK (3 million IU) and streptokinase (1.5 million IU) in 
two hours with similar efficacy and safety results (Table 
2)[22,23]. 
Currently the ACCP guidelines[6] recommend short 
treatments of 2 h of fibrinolytic agents for massive PE 
Table 1  Predictive factors of severity and 30-d mortality
Predictors of 30-d mortality
Cardiac failure
COPD
Systolic pressure < 100 mmHg
Age over 70 yr
Heart rate > 100 bpm
ECG signs of RV dysfunction
Elevated cardiac biomarkers (Troponins, BNP, H-FABP)
CT findings: RV enlargement
Echocardiography findings: 
RV hypokinesis and dilatation 
Deviation of the interventricular septum
Tricuspid regurgitation > 2.6 m/s
Loss of inspiratory collapse of the inferior vena cava
Patent foramen ovale
Modified from Pizza et al[16]. COPD: Chronic obstructive pulmonary 
disease; bpm: Beat per minute; ECG: Electrocardiogram; BNP: Brain-type 
natriuretic peptide; H-FABP: Heart-type fatty acid-binding protein; RV: 
Right ventricle; CT: Computed tomography. 
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(Recommendation Grade 2C). In submassive PE, the 
ACCP[6]. recommends the use of fibrinolytics only in 
cases of clinical deterioration despite anticoagulation. In 
this case the doses to be used will be the same as for 
the massive PE, however some advocate for half-dose 
of r-TPA to decrease the bleeding risk.
Regarding the route of administration, the systemic 
effect is recommended in severe PE. However, when 
the patient has a high risk of bleeding or the systemic 
therapy hasn’t been effective, a lower-dose fibrinolytic 
therapy can be administered via catheter placed within 
the pulmonary artery or directly in the thrombus; 
this procedure may be performed with or without 
thrombectomy and/or clot fragmentation. Regarding 
massive PE, Kuo et al[9] in their recent multicenter 
study, showed that a catheter-directed therapy (CDT) 
improves pulmonary hypertension and RV function 
effectively without more complications.
When pharmacological treatment (anticoagulant 
or thrombolysis) fails or is contraindicated, an IVCf 
can be implanted to prevent the migration of thrombi 
to the lung from a previous DVT (Recommendation 
Grade 1B). There are many types of filters on the 
market with similar efficacy and safety, although there 
are few comparative studies[7]. The development of 
the retrievable filters has expanded its use since it is 
possible to recover the IVCf once as filtration is no 
longer necessary or the risk of embolism has been 
resolved[24,25]. In the long term, The IVCf may become 
a thrombogenic device as and therefore may require 
long-term anticoagulant treatment to mitigate the risk 
of filter-related thrombosis[26]. The FDA in 2010 issued 
a recommendation advising the recovery of every IVCf 
as soon as possible, once they had fulfilled their clinical 
mission[27]. Only temporary IVCf should be implanted 
based on the available evidence and routinely removed 
within 25-54 d according to the guidelines of the 
USFDA[28].
ENDOVASCULAR TECHNIQUES FOR THE 
TREATMENT OF MASSIVE PE
The first objective in a massive PE is to remove the 
artery obstruction in order to reduce pulmonary hy-
pertension and RV failure. Endovascular treatment by 
different devices of fragmentation or thrombectomy 
can help reduce the thrombotic load and improve the 
reperfusion of the vascular system. At the same time, 
thrombus fragmentation exposes a larger surface area 
of clot, producing a superior efficacy of the fibrinolytic 
therapy (Figure 1)[29].
Systemic fibrinolytic therapy has demonstrated to 
flow in other continuous patent vessels without acting 
directly into the clogged vessel. Some studies have 
shown a more precise action of these drugs when it was 
administered directly within the thrombus with excellent 
results[30]. Several devices have been used to perform a 
CDT with different levels of efficacy[12,29,31-41].
The simplest and most widespread technique is the 
use of pigtail catheters to fragment the thrombus by 
continuous rotation of the catheter[42]. The proximal 
fragmentation of the thrombus leads to distal embo-
lization of smaller thrombi (Figure 1), however some 
authors have reported pulmonary hypertension with 
the use of this technique[43]; other authors or many 
years had shown the contrary[8,34,44,45]. Other devices 
like balloon catheters of different sizes are inflated 
and deflated successively for the fragmentation of 
the thrombi. The aspiration of thrombi located in the 
pulmonary arteries can also be attempted with aspiration 
of large caliber catheters (8 French or more)[14]. All of 
them are used in combination with locally administered 
fibrinolytic agents through an intra-thrombus catheter. 
The great advantage of these devices although of 
dubious effectiveness, is that they are simple to use and 
available at a low price (Figure 2).
The mechanical devices of thrombectomy or endo-
vascular aspiration can be classified by their mechanism 
of action in: Rheolytic, rotational, aspiration and frag-
mentation (Table 3)[39].
The AngioJet (Boston Scientific Voisins-le-Breto-
nneux, France) rheolytic system is a thrombectomy 
designed to aspirate the thrombus using the Venturi-
Bernoulli effect. With high-pressure jets and velocity 
in the distal holes of the system, it creates a zone 
of low pressure and a suction effect. The system 
Table 2  Fibrinolytic treatments used in massive pulmonary 
embolism
Fibrinolytic agent Infusion treatment 12-24 h Short infusion treatment
Urokinase 4400 IU/kg (bolus/30 
min)
+
4400 IU/kg per hour 12-24 h
3 million IU/2 h
Streptokinase 250.000 IU (bolus/15 min)
+
100000 IU/h 12-24 h
1.5 million IU/2 h
r-tPA N/A 100 mg/2 h
N/A: Not applicable. Figure 1  Schematic representation of thrombus fragmentation by a me­
chanical thrombolysis resulting a distal embolization of smaller thrombi, 
creating a larger surface area of the clot improving the efficacy of the 
thrombolytic agent therapy.
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has been associated with multiple complications 
including bradycardia, blockage, hemoglobinuria, renal 
insufficiency, severe hemoptysis, even procedural de-
ath[29], which the FDA advises against its use as the first 
therapeutic option in PE[32,46].
The Helix Clot Buster (Medtronic Minneapolis, United 
States), formerly known as the Amplatz thrombectomy 
device, is an FDA-approved device for the endovascular 
treatment to treat dialysis grafts and AV fistulas, 
but hasn’t been used for thrombectomy in PE. It is a 
reinforced polyurethane catheter of 7 Fr with lengths 
from 75 to 120 cm. At its distal end it has a metal 
impeller that is connected to a motor that rotates more 
than 140000 rpm, which generates a pressure of 30-35 
psi that allows the suction of the thrombus[33].
Two relatively new devices are Aspirex and Rotarex 
(Straub, Wangs, Switzerland). The Aspirex catheter 
acts as the archimedean screw, that rotates inside the 
catheter lumen; this spiral mechanism is connected to 
an active motor producing a thrombus aspiration. A 
catheter system transports the aspirated material to a 
manifold. Its clinical results are promising but there are 
no controlled studies that can support it (Figure 3)[18].
The Indigo mechanical aspiration system (Penumbra 
Alameda, United States) is an aspiration thrombectomy 
catheter system. A large caliber (8 Fr) catheter with 
A B C
D E F
Figure 2  The great advantage of these devices although of dubious effectiveness, is that they are simple to use and available at a low price. A, B: 
Pulmonary angiography and CT angiography, of a 37-year-old male patient diagnosed with a massive pulmonary embolism; C: Catheter drug therapy, and mechanical 
thrombolysis; D, E: Schematic representation of mechanical thrombolysis and the infusion of fibrinolytic agents through the pigtail catheter; F: Pulmonary angiography 
after 24 h of perfusion with 100000.00 UI/h of urokinase, showing no residual occlusion. 
Table 3  Fragmentation and aspiration devices used in the endovascular treatment of pulmonary embolism
Endovascular mechanisms 
of thrombectomy and 
thrombolysis
Rheolytic Rotational Aspiration Fragmentation Ultrasound
Devices Angio Jet Rotarex Indigo Fogarty arterial balloon 
embolectomy catheter
Ekos Sonic




Mechanism Pressurized saline 
or fibrinolytic agent 
injection through the 
catheter in the distal 




coil within the 
catheter, creating a 
negative pressure 
and aspiration of the 
thrombus
Aspiration pump 
that provides a high 
negative pressure of 
suction with a guide-
wire (separator) to 
create fragmentation of 
the thrombus
Performing balloon 
sweeps or manually 
rotation of the standard 
Pig-tail to fragment the 
thrombus
Ultrasound emitting 
catheter localized within 
the thrombus to generate 
an acoustic field creating 
a more lytic dispersion of 
the drug infused
Modified from Barjaktarevic et al[39].
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dirigible and soft tip, allows easy aspiration of the 
thrombi housed in the pulmonary arteries due to the 
great suction power of the suction pump. Several 
studies are being performed to evaluate safety and 
efficacy of this device (Figure 4).
The EKOSonic system (Ekosonic endovascular 
System BTG Riverside Way, Watchmoor Park, United 
Kingdom) is the only device approved by the FDA 
to treat PE. This system generates an acoustic pulse 
fibrinolytic agent, which have shown satisfactory results 
to treat massive and submassive PE. The catheter 
lodges in its interior a sophisticated catheter with an 
ultrasonic core to effectively target an entire clot. 
This catheter uses two systems, the ultrasound and 
the infusion of the fibrinolytic agent. It consists of a 
5.4 Fr catheter and has a functional distal tip ranging 
from 6 to 50 cm in length[41]. However, acoustic field 
catheters may accelerate dispersion, clinical advantage 
vs standard infusion catheters is unclear and unproven 
(Figure 5).
RESULTS OF ENDOVASCULAR 
TECHNIQUES FOR THE TREATMENT OF 
PE
There are few randomized studies comparing both 
types of fibrinolytic administration (systemic vs CDT)[47]. 
The first study on which the ACCP recommendations 
are based, was published by Verstraete et al[48]. In this 
study, 34 patients were treated with local or systemic 
thrombolysis and did not observe significant differences 
between the two groups in terms of efficacy and com-
plications. It should be noted that in the CDT group, the 
fibrinolytic agent was administered from the catheter 
located in a non intra-thrombus approach within the 
pulmonary artery. The meta-analysis published in 2008 
about 35 studies, indicates that 594 patients with PE 
were treated with CDT and of them 67% received intra-
thrombotic thrombolysis during CDT[31]. Treatment with 
CDT with or without thrombolysis produced a clinical 
success of 86.5% (356/535). Similar results have now 
been obtained by combining local fibrinolytic agent with 
thrombus fragmentation or aspiration[8,49]. PERFECT, 
a multicenter trial with a total of 101 patients were 
treated with CDT and achieved a clinical success of 
85.7% of the patients diagnosed with massive PE and 
97.3% in submassive PE[9]. The use of new devices 
for fragmentation and/or aspiration of the thrombi can 
improve these results. The use of ultrasound through 
a 5.4 Fr catheter with infusion of fibrinolytic leads to 
rapid lysis of the thrombi located in the pulmonary 
artery[40,50,51]. Seattle Ⅱ, a prospective study of 150 
patients diagnosed with massive or submassive PE 
using EKO-sonic and a low dose of r-TPA through CDT, 
reduced the RV/LV ratio measured with CT by 25% in 48 
h, showed a 30% improvement of the systolic pressure 
and another 30% in the pulmonary artery obstruction[41]. 
These results, however, according to several authors, do 
not represent significant differences with those obtained 
by the standard CDT[49,52].
COMPLICATION
In a randomized study of 1006 patients with sub-
massive PE the risk of intracranial hemorrhage also 
with systemic thrombolysis is 3%-5% in the various 
studies[3,53]. Other complications have been described 
such as: Bradyarrhythmia, cardiac tamponade, rup-
ture or dissection of the pulmonary arteries, severe 
hemoptysis, renal failure and hemoglobinuria. Major 
complications (major bleeding and death) ranged from 
0%-3%[9,45,49]. A meta-analysis of PE treated with CDT 
had a 2.4% of major complications and 7.9% of minor 
complications[29].
CONCLUSION
CDT is an accepted therapeutic technique for the 
treatment of acute massive PE and cases of submassive 
PE with RV dysfunction or failure. However it requires a 
well-trained medical and interventional team to achieve 
best results. Further clinical studies are needed to 
analyze the CDT protocol for massive and submassive 
PE, define which submassive PE patients should be 
treated with early CDT, and determine if early CDT 
treatment can decrease the long-term risk of developing 
chronic thromboembolic pulmonary hypertension.
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